Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
14.82
-0.38 (-2.50%)
Mar 6, 2026, 3:39 PM EST - Market open
Dyne Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 69.85 | 62.48 | 31.4 | 28.2 | 28.72 | |
| Research & Development | 398.33 | 281.41 | 210.76 | 142.76 | 121.31 | |
| Operating Expenses | 468.18 | 343.89 | 242.16 | 170.96 | 150.03 | |
| Operating Income | -468.18 | -343.89 | -242.16 | -170.96 | -150.03 | |
| Interest Expense | -6.19 | - | - | - | - | |
| Interest & Investment Income | 29.86 | 26.92 | 7.64 | 2.92 | 0.74 | |
| Currency Exchange Gain (Loss) | -1.73 | -0.49 | -1.39 | -0.02 | - | |
| EBT Excluding Unusual Items | -446.24 | -317.45 | -235.91 | -168.07 | -149.28 | |
| Gain (Loss) on Sale of Investments | 0.03 | 0.04 | -0.02 | -0.03 | -0.01 | |
| Pretax Income | -446.21 | -317.42 | -235.94 | -168.1 | -149.29 | |
| Net Income | -446.21 | -317.42 | -235.94 | -168.1 | -149.29 | |
| Net Income to Common | -446.21 | -317.42 | -235.94 | -168.1 | -149.29 | |
| Shares Outstanding (Basic) | 128 | 94 | 60 | 52 | 51 | |
| Shares Outstanding (Diluted) | 128 | 94 | 60 | 52 | 51 | |
| Shares Change (YoY) | 36.43% | 57.74% | 14.83% | 2.13% | 253.54% | |
| EPS (Basic) | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | |
| EPS (Diluted) | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | |
| Free Cash Flow | -423.92 | -294.75 | -188.89 | -156.71 | -123.18 | |
| Free Cash Flow Per Share | -3.30 | -3.13 | -3.17 | -3.02 | -2.42 | |
| EBITDA | -466.14 | -342.21 | -240.49 | -169.28 | -148.94 | |
| D&A For EBITDA | 2.05 | 1.67 | 1.67 | 1.68 | 1.09 | |
| EBIT | -468.18 | -343.89 | -242.16 | -170.96 | -150.03 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.